Tagged Articles

medication 93 articles

DEA introduces new drug take-back program to combat prescription drug abuse

A new Drug Enforcement Administration (DEA) rule aims to combat a growing epidemic of prescription drug addiction and abuse by authorizing pharmacies, hospitals, clinics, and others to serve as drop-off sites for unused prescription medications. Attorney General Eric Holder said that the new regulation will help save lives and protect families from the dangers of prescription drug misuse. In 2011, unintentional prescription drug overdoses accounted for more than half of the 41,300 drug overdose deaths in the U.S. Prescription opioids, which are increasingly prescribed for pain relief, are particularly addictive and likely to be abused. Opioid pain killer overdose caused ... Read More

Cancer Monthly urges Actos users to be aware of the signs of bladder cancer

Cancer Monthly, an information site about the disease, is advising people who take or have taken the type 2 diabetes drug Actos to be aware of the symptoms of bladder cancer following a $9 billion judgment against the drug company to compensate a single bladder cancer victim. According to court testimony, the plaintiff took Actos for five years before he was diagnosed with bladder cancer in 2011. Also that year, the Food and Drug Administration (FDA) issued a warning that people who took Actos for a year were 40 percent more likely to develop bladder cancer. The FDA ordered Takeda ... Read More

Takeda hit with more sanctions in Actos bladder cancer trial

Takeda Pharmaceuticals was hit by sanctions for its defense counsel’s “very disrespectful” conduct during the trial of two women who claim the drug company’s type 2 diabetes medication Actos caused them to develop bladder cancer. The trial of Delores Cipriano and Bertha Triana began in February, however the court noted that “defense counsel has repeatedly engaged in disruptive and disrespectful behavior toward the court, which is well-documented in the record. As a result, the court’s decision to impose sanctions is based on the aforementioned cumulative conduct of counsel in disobeying court orders and disrupting court procedings.” Plaintiffs reported they had ... Read More

Risperdal makers marketed bipolar drug to children despite alarming side effects

In 1993, the Food and Drug Administration (FDA) approved the antipsychotic medication Risperdal (risperidone) to treat manic or mixed delusional episodes in adult patients with schizophrenia. Fourteen years later that the FDA expanded the indication to include children and adolescents, but only for the treatment of schizophrenia and bipolar disorder. Yet, between 1993 and 2008, Risperdal was being administered “off label” to thousands of children, many of whom suffered complications from the drug, including death. In fact, the FDA ordered Johnson & Johnson in 2001 to change the drug’s label stating that the safety and efficacy of Risperdal in children ... Read More

FDA approves medical device to treat migraine headaches

The Food and Drug Administration (FDA) has approved a novel new nerve-stimulating headband designed to treat and prevent migraine headaches. The device offers a new option for migraine sufferers who cannot tolerate migraine medications. The Cefaly device is a battery-powered plastic headband that is worn across the forehead. The band emits a low electrical current through an adhesive electrode to help stimulate nerves that trigger migraines. The headband is designed to be worn for up to 20 minutes a day in adult patients age 18 and older. The device was approved based on a 67-person study that showed those using ... Read More

Once-weekly injectable type 2 diabetes treatment just as effective as Victoza

Dulaglutide, an experimental once-weekly injectable treatment for type 2 diabetes, works just as well as the daily injectable drug Victoza (liraglutide), according to a new data from a clinical trial pitting the two diabetes drugs against each other. Even though dulaglutide did not perform better than Victoza, the results are considered a huge success since injectable medications are generally not favored by patients. Previous clinical trials have compared dulaglutide with the insulin drug metformin, and newer type 2 medications Byetta and Januvia, the latter of which is a leader in diabetes treatments with sales topping $4 billion a year. Dulaglutide ... Read More

Experimental genital herpes treatment fares well in small clinical trial

Clinical trials are showing promise for an experimental drug to treat genital herpes, a common, highly contagious, and incurable infection usually spread through sexual contact. The drug, called pritelivir, was found to substantially decrease “viral shedding,” which is the amount of time the virus was active and potentially transmissible to sexual partners. Genital herpes is caused by the herpes simplex virus, most often from a strain known as HSV-2. The infection can cause painful sores around the genitals, rectum or mouth, which can be reactivated periodically. Sometimes people experience no symptoms or only mild ones, however the disease can be ... Read More

FDA rejects novel drug for multiple sclerosis, cites safety concerns

The Food and Drug Administration (FDA) has rejected Sanofi’s Genzyme unit’s bid for the multiple sclerosis (MS) drug alemtuzumab (Lemtrada), citing inadequate data and concerns about life threatening side effects. The drug company says it disagrees with the FDA’s decision and will appeal. MS is a debilitating autoimmune disease that affects the central nervous system, causing symptoms such as coordination problems and spasticity. Alemtuzumab is a novel treatment designed to down-regulate the inflammatory activity in MS. It is administered as an initial five-day course of infusions followed by a second three-day course a year later. The drug was pitted against beta-interferon, ... Read More

FDA panel recommends approval of new type 2 diabetes drug dapagliflozin

A Food and Drug Administration (FDA) advisory panel has voted to recommend the approval of a new type of type 2 diabetes medication two years after it was rejected by regulators based on concerns that it could increase the risk of cancer and cardiovascular events. Dapagliflozin, from Bristol-Myers Squibb and AstraZeneca, is a once-daily pill in a new class of diabetes medications known as SGLT-2 inhibitors. The FDA rejected the drug in January 2012, saying it needed more data to asses breast and bladder cancer concerns as well as heart risks. The drug companies resubmitted the application with several new ... Read More

Actos label updated to advise against use in pediatric patients with type 2 diabetes

The type 2 diabetes drug Actos is not recommended for children or adolescents because of potentially dangerous side effects including fluid retention and congestive heart failure, fractures and urinary bladder tumors, according to an update to the drug’s safety label. Actos, known generically as pioglitazone, is an oral diabetes medicine that helps control blood sugar levels. It is approved for use in adults with type 2 diabetes, a chronic condition often associated with obesity and a sedentary lifestyle. The condition was once known as “adult onset diabetes,” however, with increasing childhood obesity, more children and adolescents are being diagnosed with ... Read More